LIGAND PHARMACEUTICALS INCORPORATED (LGND) Operating cash flow 2016–2025
LIGAND PHARMACEUTICALS INCORPORATED (LGND) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$49.4MFY2025 · since FY2016: $60.7M → $49.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $49.4M | -49.1% |
| FY2024 | $97.0M | +95.8% |
| FY2023 | $49.6M | -64.0% |
| FY2022 | $137.8M | +74.9% |
| FY2021 | $78.8M | +44.4% |
| FY2020 | $54.6M | +286.1% |
| FY2019 | -$29.3M | -115.1% |
| FY2018 | $194.1M | +119.1% |
| FY2017 | $88.6M | +45.8% |
| FY2016 | $60.7M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More LGND financial trends
LGND RevenueLGND Net incomeLGND Net marginLGND Gross profitLGND Gross marginLGND Operating incomeLGND Operating marginLGND Free cash flowLGND Capital expendituresLGND Return on equityLGND Stock buybacksLGND Dividends paidLGND Total assetsLGND Total liabilitiesLGND Shareholders’ equityLGND overview →